Provider-Patient Interactions and Engagement in HIV/HCV Care

HIV HCV Curriculum Logo

This lesson reviews provider-level and patient-level barriers to patient engagement in HIV/HCV care, and how they can be addressed.

Download Slides

References

  1. Oramasionwu CU, Moore HN, Toliver JC. Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review. AIDS Patient Care STDS. 2014 May;28(5):228-39.
  2. Osilla KC, Wagner G, Garnett J, et al. Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment. AIDS Patient Care STDS. 2011 Sep;25(9):533-8.
  3. Bruggmann P. Accessing hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat. 2012 Dec;19(12):829-35.
  4. Wagner G, Ryan G, Osilla KC, Bhatti L, Goetz M, Witt M. Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. AIDS Patient Care STDS. 2009 Sep;23(9):715-25.
  5. Vutien P, Hoang J, Brooks L Jr, Nguyen NH, Nguyen MH. Racial disparities in treatment rates for chronic hepatitis C: analysis of a population-based cohort of 73,665 patients in the United States. Medicine (Baltimore). 2016 May;95(22):e3719.
  6. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012 Feb;32 Suppl 1:151-6.
  7. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010 Mar;51(3):729-33.
  8. Center for Disease Control and Prevention. HIV and Viral Hepatitis. March 2014. Accessed July 10, 2017.
  9. Jost J, Goldsamt LA, Harocops A, Kobrak P, Clatts MC. Hepatitis C knowledge among new injection drug users. Drugs: Education, Prevention and Policy. 2010;17(6):821-834. Available at: http://www.tandfonline.com/doi/full/10.3109/09687630902858948. Accessed April 19, 2017.
  10. Wagner GJ, Ryan GW. Hepatitis C virus treatment decision-making in the context of HIV co-infection: the role of medical, behavioral and mental health factors in assessing treatment readiness. AIDS. 2005 Oct;19 Suppl 3:S190-8.
  11. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. What do patients consider when making decisions about treatment for hepatitis C? Am J Med. 2005 Dec;118(12):1387-91.
  12. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007 May;52(5):1168-76.
  13. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013 Mar;207 Suppl 1:S19-25.
  14. Swan D, Long J, Carr O, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS. 2010 Dec;24(12):753-62.
  15. Mahadevan M, Amutah N, Ramos L, et al. Project THANKS: a socio-ecological framework for an intervention involving HIV positive African American women with comorbidities. J Health Dispar Res Pract. 2014 Winter;7(2):87-105.
  16.  El-Zayadi AR. Hepatitis C comorbidities affecting the course and response to therapy. World J Gastroenterol. 2009 Oct 28;15(40):4993-9.
  17. Modabbernia A, Poustchi H, Malekzadeh R. Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat Mon. 2013 Jan;13(1):e8340.
  18. Lekas HM, Siegel K, Leider J. Felt and enacted stigma among HIV/HCV-coinfected adults: the impact of stigma layering. Qual Health Res. 2011 Sep;21(9):1205-19.
  19. Proeschold-Bell RJ, Hoeppner B, Taylor B, et al. An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. AIDS Behav. 2011 Nov;15(8):1721-31.
  20. Ho SB, Brau N, Cheung R, et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol. 2015 Nov;13(11):2005-14.e1-3.
  21. Jonas MC, Rodriguez CV, Redd J, Sloane DA, Winston BJ, Loftus BC. Streamlining screening to treatment: the hepatitis C cascade of care at Kaiser Permanente Mid-Atlantic States. Clin Infect Dis. 2016 May 15;62(10):1290-96.
  22. Oramasionwu CU, Moore HN, Toliver JC. Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review. AIDS Patient Care STDS. 2014 May;28(5):228-39.